Evidence map›Paper›PMID 37118898›Full record

ArticleJournal of diabetes investigation2023

Impact of the COVID-19 pandemic on the glycemic control in people with diabetes mellitus: A retrospective cohort study.

Kanako Ohkuma, Mika Sawada, Masakazu Aihara, Shunsuke Doi, Rie Sekine, Satoshi Usami, Kazuhiko Ohe, Naoto Kubota, Toshimasa Yamauchi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Kanako Ohkuma *Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mika Sawada *Department of Clinical Nutrition Therapy, The University of Tokyo Hospital, Tokyo, Japan.
Masakazu AiharaDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shunsuke DoiDepartment of Healthcare and Information Management, University of Tokyo Hospital, Tokyo, Japan.
Rie SekineDepartment of Clinical Nutrition Therapy, The University of Tokyo Hospital, Tokyo, Japan.
Satoshi UsamiGraduate School of Education, The University of Tokyo, Tokyo, Japan.
Kazuhiko OheDepartment of Healthcare and Information Management, University of Tokyo Hospital, Tokyo, Japan.
Naoto KubotaDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-3336-2767
Toshimasa YamauchiDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
University of Tokyo Hospital · JPThe University of Tokyo · JPTokyo Health Care University · JPJapan Graduate School of Education University · JPZero to Three · US

Funding

JSPS KAKENHI
6 · The paper itself

Abstract

aimTo investigate the impact of the COVID-19 pandemic and its preventive measures on the glycemic and lipid control in people with diabetes mellitus (DM). MATERIALS AND

methodsWe conducted this retrospective cohort study from April 2019 to March 2021; we termed the period from April 2019 to March 2020 as the pre-COVID-19 period, and the period from April 2020 to March 2021 as the COVID-19 period, and divided each of these two periods into four quarters.

resultsIn the 1st quarter of the COVID period, when the Japanese government declared the first public health emergency, 3,465 people with diabetes mellitus were receiving treatment, which was 10.4% lower than that in the pre-COVID period. The annual mean HbA1c level was significantly elevated in the COVID-19 period. The annual mean total cholesterol (TC) and triglyceride (TG) levels were also significantly higher in the COVID-19 period. Although there were no significant differences in the glycemic control or annual medication between the two periods in people with type 1 diabetes mellitus, the annual mean HbA1c, TC, and TG levels were significantly higher in the COVID-19 period in people with type 2 diabetes mellitus. Furthermore, a significant increase in the percentage of prescriptions for glinides, biguanides, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists for people with type 2 diabetes mellitus was observed in the COVID period.

conclusionsIt appears from our study that COVID-19 and its preventive measures had a negative impact on the glycemic and lipid control in people with diabetes mellitus.

Indexed as

COVID-19Diabetes Mellitus, Type 2Blood GlucoseGlycated HemoglobinGlycemic ControlHumansHypoglycemic AgentsLipidsPandemicsRetrospective StudiesBlood GlucoseGlycated HemoglobinHypoglycemic AgentsLipidsCOVID-19, Glycemic control, Lipid control

Identifiers

PMID37118898
PMCPMC10360387
OpenAlexW4367368754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.